P53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes

DNA and Cell Biology

Volumn 28, Issue 12, 2009, Pages 615-623

  Rath, Pramod C ^a   Mukhopadhyay, Tapas ^b  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ADENOVIRUS VECTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CYTOPLASM; DNA; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LUNG NEOPLASMS; MICE; NF-KAPPA B; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

ADENOVIRIDAE;

EID: 72649085451     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2008.0839     Document Type: Article

References (52)

1. Asker, C., Wiman, K.G., and Selivanova, G. (1999). p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 265, 1-6.
2. Baldwin, A.S., Jr. (1996). The NF-kappa B and I kappa B proteins: New discoveries and insights. Ann Rev Immunol 14, 649-683.
3. Begg, A.A., and Baltimore, D. (1996).An essential role for NF-kB in preventing TNF-a-induced cell death. Science 274, 782-784.
4. Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature (Lond) 411, 355-365.
5. Bu, S.Z., Huang, Q., Jiang, Y.M., Min, H.B., Hou, Y., Guo, Z.Y., Wei, J.F., Wang, J. W., Ni, X., and Zheng, S.S. (2006). mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Apoptosis 11, 413-425.
6. Chaturvedi, M., LaPushin, R., and Aggarwal, B.B. (1994). Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response. J Biol Chem 269, 14575-14583.
7. Dahut, W.L., Lakhani, N.J., Gulley, J.L., Arlen, P.M., Kohn, E.C., Kotz, H., McNally, D., Parr, A., Nguyen, D., Yang, S.X., Steinberg, S.M., Venitz, J., Sparreboom, A., and Figg, W.D. (2006). Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5, 22-27.
8. Davoodpour, P., and Landstrom, M. (2005). 2-Methoxyestradiolinduced apoptosis in prostate cancer cells requires Smad7. J Biol Chem 280, 14773-14779.
9. Dey, A., Tergaonkar, V., and Lane, D.P. (2008). Double-edged swords as cancer therapeutics: Simultaneously targeting p53 and NF-kB pathways. Nat Rev Drug Dis 7, 1031-1040.
10. Evan, G.I., and Vousden, K.H. (2001). Proliferation, cell cycle and apoptosis in cancer, Nature (Lond) 411, 342-348.
11. Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., Cai, D.W., Owen-Schaub, L.B., and Roth, J.A. (1993). A retroviral wildtype p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53, 4129-4133.
12. Fukazawa, T., Fujiwara, T., Morimoto, Y., Nishizaki, M., Kadowaki, Y., Hizuta, A., Owen-Schaub, L.B., Roth, J.A., and Tanaka, N. (1999). Differential involvement of the CD95 (Fas=APO-1) receptor=ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene 18, 2189-2200.
13. Gao, N., Rahmani, M., Dent, P., and Grant, S. (2005). 2- Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Aktdependent process. Oncogene 24, 3797-3809.
14. Garcia, G.E., Wisniewski, H.G., Lucia, M.S., Arevalo, N., Slaga, T.J., Kraft, S.L., Strange, R., and Kumar, A.P. (2006). 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 12, 980-988.
15. Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Ann Rev Immunol 16, 225-260.
16. Gui, Y., and Zheng, X.L. (2006). 2-Methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells. Hypertension 47, 271-280.
17. Guo, C., Gasparian, A.V., Zhuang, Z., Bosykh, D.A., Komar, A.A., Gudkov, A.V., and Gurova, K.V. (2009). 9-Aminoacridinebased anticancer drugs target the PI3K=AKT=mTOR, NF-kB and p53 pathways. Oncogene 28, 1151-1161.
18. Hagen, T., D'Amico, G., Quintero, M., Palacios-Callender, M., Hollis, V., Lam, F., and Moncada, S. (2004). Inhibition of mitochondrial respiration by the anticancer agent 2- methoxyestradiol. Biochem Biophys Res Commun 322, 923-929.
19. Hainaut, P., and Hollstein, M. (2000). p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 77, 81-137.
20. Hoeijmakers, J.H.J. (2001). Genome maintenance mechanisms for preventing cancer. Nature (Lond) 411, 366-374.
21. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. Science 253, 49-53.
22. Kagawa, S., Fujiwara, T., Hizuta, A., Yasuda, T., Zhang, W.W., Roth, J.A., and Tanaka, N. (1997). p53 expression overcomes p21-WAF1=CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene 15, 1903-1909.
23. Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304-6311.
24. Kim, S.H., Lee, S.U., Kim, M.H., Kim, B.T., and Min, Y.K. (2005). Mitogenic estrogen metabolites alter the expression of 17beta-estradiol- regulated proteins including heat shock proteins in human MCF-7 breast cancer cells. Mol Cells 20, 378-384.
25. Kumar, A.P., Garcia, G.E., Orsborn, J., Levin, V.A., and Slaga, T.J. (2003). 2-Methoxyestradiol interferes with NF-kB transcriptional activity in primitive neuroectodermal brain tumors: Implications for management. Carcinogenesis 24, 209-216.
26. Lee, Y.M., Ting, C.M., Cheng, Y.K., Fan, T.P., Wong, R.N., Lung, M.L., and Mak, N.K. (2008). Mechanisms of 2-methoxyestradiol-induced apoptosis and G2=M cell cycle arrest of nasophageal carcinoma cells. Cancer Lett 268, 295-307.
27. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
28. Liu, G., Park, Y.J., Tsuruta, Y., Lorne, E., and Abraham, E. (2009). p53 attenuates lipopolysaccharide-induced NF-kB activation and acute lung injury. J Immunol 182, 5063-5071.
29. Lowe, S.W., and Lin, A.W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485-495.
30. Maki, M.G. (1999). Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274, 16531-16535.
31. Mayo, M.W., and Baldwin, A.S. (2000). The transcription factor NF-kB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470, M55-M62.
32. Mukhopadhyay, T., and Roth, J.A. (1997). Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14, 379-384.
33. Mukhopadhyay, T., and Roth, J.A. (1998). Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 17, 241-246.
34. Newman, S.P., Ireson, C.R., Tutill, H.J., Day, J.M., Parsons, M.F., Leese, M.P., Potter, B.V., Reed, M.J., and Purohit, A. (2006). The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 66, 324-330.
35. Ponder, B.A.J. (2001). Cancer genetics. Nature (Lond) 411, 336- 341.
36. Rath, P.C., and Aggarwal, B.B. (1999). TNF-induced signaling in apoptosis. J Clin Immunol 19, 350-364.
37. Rath, P.C., and Aggarwal, B.B. (2001). Antiproliferative effects of IFN-a correlate with the down regulation of nuclear factor-kB in human Burkitt lymphoma Daudi cells. J Interferon Cytokine Res 21, 523-528.
38. Ravi, R., Mookerjee, B., Hensbergan, Y.V., Bedi, G.C., Giordano, A., El-Deiry, W.S., Fuchs, E.J., and Bedi, A. (1998). p53- mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res 58, 4531-4536.
39. Ray, G., Dhar, G., Van Veldhuizen, P.J., Banerjee, S., Saxena, N.K., Sengupta, K., and Banerjee, S.K. (2006). Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. Biochemistry 45, 3703-3713.
40. Roth, J.A. (1998). Gene replacement strategies for lung cancer. Curr Opin Oncol 10, 127-132.
41. Ryan, K.M., Ernst, M.K., Rice, N.R., and Vousden, K.H. (2000). Role of NF-kB in p53-mediated programmed cell death. Nature (Lond) 404, 892-897.
42. Shimada, K., Nakamura, M., Ishida, E., Kishi, M., and Konishi, N. (2003). Roles of p38- and c-jun NH2-terminal kinasemediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24, 1067-1075.
43. Soengas, M.S., Alarcon, R.M., Yoshida, H., Giaccia, A.J., Hakem, R., Mak, T.W., and Lowe, S.W. (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156-159.
44. Sweeney, C., Liu, G., Yiannoutsos, C., Kolesar, J., Horvath, D., Staab, M.J., Fife, K., Armstrong, V., Treston, A., Sidor, C., and Wilding, G.A. (2005). Phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer, Clin Cancer Res 11, 6625-6633.
45. Takata, H., Tomizawa, K., Matsushita, M., and Matsui, H. (2004). 2-Methoxyestradiol enhances p53 protein transduction therapy-associated inhibition of the proliferation of oral cancer cells through the suppression of NFkappaB activity. Acta Med Okayama 58, 181-187.
46. Vousden, K.H. (2000). p53: Death star. Cell 103, 691-694.
47. Wadgaonkar, R., Phelps, K.M., Haque, Z., Williams, A.J., Silverman, E.S., and Collins, T. (1999). CREB-binding protein is a nuclear integrator of nuclear factor-kB and p53 Signaling. J Biol Chem 274, 1879-1882.
48. Wallach, D., Varfolomeev, E.E., Malinin, N.L., Goltsev, Y.V., Kovalenko, A.V., and Boldin, M.P. (1999). Tumor necrosis factor receptor and Fas signaling mechanisms. Ann Rev Immunol 17, 331-367.
49. Wang, C.Y., Cusack, J.C., Jr., Liu, R., and Baldwin, A.S., Jr. (1999). Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-kB. Nat Med 5, 412-417.
50. Wang, Y., Blandino, G., and Givol, D. (1999). Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18, 2643-2649.
51. Webster, G.A., and Perkins, N.D. (1999). Transcriptional cross talk between NF-kB and p53. Mol Cell Biol 19, 3485-3495.
52. Yang, J.P., Hori, M., Takahashi, N., Kawabe, T., Kato, H., and Okamoto, T. (1999). NF-kB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18, 5177-5186.